Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

September 8, 2023

Study Completion Date

September 8, 2023

Conditions
Overactive BladderParkinson Disease
Interventions
DRUG

solifenacin

Antimuscarinic bladder relaxant, antagonizes bladder muscarinic receptors

BEHAVIORAL

Pelvic floor muscle exercise-based behavioral therapy

Multicomponent intervention including fluid management, constipation management and behavioral techniques incorporating pelvic floor muscle-exercise based urge suppression and self-monitoring to reduce overactive bladder symptoms

Trial Locations (4)

19104

Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia

23249

Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond

35233

Birmingham VA Medical Center, Birmingham, AL, Birmingham

30033-4004

Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur

All Listed Sponsors
lead

VA Office of Research and Development

FED

NCT03149809 - Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease | Biotech Hunter | Biotech Hunter